Researchers at The Ohio State University have reported laboratory findings showing that Telomir-Zn inhibited growth of canine and human osteosarcoma cell lines.
The experimental drug was tested against three cell lines: one human osteosarcoma line and two canine lines. The company reported that all three showed growth inhibition at similar low concentrations.
The findings have attracted attention because canine osteosarcoma shares several biological and clinical characteristics with human osteosarcoma, making naturally occurring canine cancer an important translational research model.
However, the current evidence remains preclinical. The experiments were conducted on cells in vitro rather than in dogs, and the published industry report did not provide detailed numerical data on concentrations or the degree of inhibition. Telomir has discussed a possible future in-vivo study in dogs with naturally occurring osteosarcoma, but no clinical efficacy result is currently established.
The development nevertheless illustrates the growing importance of comparative oncology, where veterinary cancer research can potentially contribute to therapeutic development for both animal and human medicine.
